Looking back on 2022, inspired by the Year in Reviews on p67

NAFLD, MAFLD and obesity: brothers in arms?

  • Mariana Verdelho Machado
  • Helena Cortez-Pinto
Year in Review

Announcements

  • Image shows organs, neurons and microbes in the spotlight

    Leading experts describe their key advances of the year. Topics covered include: IBD; IBS; pancreatic cancer; gut-brain axis; gut microbiota; NAFLD and obesity; ALD

  • Image of face mask and glove

    FREE ACCESS - This Collection covers the COVID-19 pandemic and its implications for patients with gastrointestinal and liver diseases.

  • Image of Nature Reviews Gastro twitter logo

    Follow us for news about the journal and the latest updates from the gastroenterology and hepatology field.

Advertisement

  • A careful integration of the effectiveness and safety of the therapies for inflammatory bowel disease, considering patients’ disease risks, treatment complications and preferences, is warranted to inform the positioning of therapies in clinical practice. Precision medicine might help choose the best option for an individual patient.

    • Siddharth Singh
    Clinical Outlook
  • The feasibility of long-term organ preservation ex vivo has been reported for the first time with proof of concept in human transplantation. Here, we discuss the possible applications of this novel technology in the clinical setting.

    • Dilmurodjon Eshmuminov
    • Pierre-Alain Clavien
    Clinical Outlook
  • A new report from the World Health Organization has evaluated the risks of dietary exposure to nanoplastic and microplastic particles (NMPs) to human health. Although challenges in the detection of NMPs in food and beverages remain, it is clear that humans are being exposed. Presently, no convincing evidence of adverse health effects are found, but major knowledge gaps remain.

    • Luc J. W. van der Laan
    • Thijs Bosker
    • Willie J. G. M. Peijnenburg
    Comment
  • The European Medicines Agency safety committee has revisited the label and recommended the use of Janus kinase inhibitors in patients with certain risk factors only if no suitable treatment alternatives are available. Although regulatory decisions are key to place therapeutic options based on safety, broad restrictions might lead to unintended consequences without an individualized benefit–risk evaluation.

    • Silvio Danese
    • Virginia Solitano
    • Laurent Peyrin-Biroulet
    Comment
Red keys on a light pink background

Key Advances in Gastroenterology & Hepatology

The Key Advances in Gastroenterology & Hepatology collection offers expert insight into the most important discoveries made each year, and is an essential resource for students, physicians and clinical researchers.
Collection

Advertisement

Nature Careers

Events

Jobs

Advertisement